Cagrilintide is a long-acting amylin receptor agonist derived from a modified version of the endogenous peptide amylin. In research environments, it is primarily studied for its effects on energy balance and metabolic regulation. Cagrilintide is engineered to have enhanced receptor affinity and a significantly prolonged half-life compared to native amylin, allowing for more sustained biological activity in experimental models.
Mechanistically, Cagrilintide interacts with the calcitonin receptor complex—formed by the calcitonin receptor and receptor activity-modifying proteins (RAMPs)—to influence pathways involved in appetite regulation, gastric emptying, and energy expenditure. In preclinical studies, it has demonstrated a capacity to suppress food intake, delay gastric motility, and contribute to reduced body weight when administered chronically.
Due to its pharmacological profile, Cagrilintide is often co-researched with GLP-1 receptor agonists to explore potential additive or synergistic effects on metabolic outcomes. This has positioned it as a compound of interest in models investigating combinatorial peptide therapies targeting multiple pathways involved in energy homeostasis.
Note: Cagrilintide is intended for research purposes only and is not approved for human consumption. All products are shipped in lyophilized form and must be reconstituted to a liquid for research and testing. We are unable to provide any dosing instructions. All products should be considered pharmaceutical grade.
